EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials

Danielle Lilly Nicholls iD, Maria C Xu iD, Luna Zhan iD, Divya Sharma, Katrina Hueniken, Kaitlyn Chiasson, Mary Wahba, M Catherine Brown iD, Benjamin Grant, Jeremy Shapiro, Christos S Karapetis iD, John Simes iD und 5 weitere

JCO Clinical Cancer Informatics · 2025

DOI: 10.1200/cci.24.00114 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JCO Clinical Cancer Informatics, 2025. Verfasst von Danielle Lilly Nicholls und 16 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cetuximab, Colorectal Neoplasms, Machine Learning. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Cetuximab (CET), targeting the epidermal growth factor receptor, is a systemic treatment option for patients with colorectal cancer. One known predictive factor for CET efficacy is the presence of CET-related rash; other putative toxicity factors include fatigue and nausea. Analysis of early CET-associated toxicities may reveal patient subpopulations that clinically benefit from long-term CET treatment. METHODS We analyzed data from CO.20 (ClinicalTrials.gov identifier: NCT00640471 ) trial arms, CET + brivanib alaninate (BRIV) (n = 376) and CET + placebo (n = 374), and CO.17 (ClinicalTrials.gov identifier: NCT00079066 ) trial arms, CET (+best supportive care [BSC]; n = 287) and BSC only (n = 285). Patients were clustered into subpopulations using KmL3D, a machine learning method, to analyze 14 joint longitudinal toxicity trajectories from weeks 0 to 8 of treatment. Landmark survival analyses were performed from 8 weeks after treatment initiation. Regression analyses assessed the relationship between subpopulations and plasma CET concentrations. Three supervised machine learning models were developed to assign patients in the CO.20-CET trial arm into subpopulations, which were then validated using CO.20-CET-BRIV and CO.17-CET trial arm data. RESULTS Joint longitudinal toxicity clustering revealed dichotomous high- and low-toxicity clusters, with all CET-containing arms showing consistent toxicity trajectories and characteristics. High-toxicity clusters were associated with male predilection, fewer metastatic sites, fewer colon-only primaries, and higher body mass indices. In CO.20 trial samples, higher toxicity clusters were associated with improved overall survival and progression-free survival outcomes (adjusted hazard ratios ranging from 2.21 to 4.36) and higher CET concentrations ( P = .003). The random forest predictive model performed the best, with an AUC of 0.981 (0.963-0.999). CONCLUSION We used an innovative machine learning approach to analyze longitudinal joint drug toxicities, demonstrating their role in predicting patient outcomes through a putative pharmacokinetic mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCetuximabColorectal NeoplasmsMachine LearningAgedFemaleHumansMaleMiddle AgedCanadaNeoplasm Metastasis

Substanzen

Cetuximab

Autor:innen und Institutionen

  • Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Cabrini Hospital and Monash University, Melbourne, VIC, Australia.
  • Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.
  • NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.

ORCID-Profile: Danielle Lilly Nicholls, Maria C Xu, Luna Zhan, M Catherine Brown, Christos S Karapetis, John Simes, Dongsheng Tu, Eric Chen, Geoffrey Liu

Zitieren

APA

Nicholls, D. L., Xu, M. C., Zhan, L., Sharma, D., Hueniken, K., Chiasson, K., Wahba, M., Brown, M. C., Grant, B., Shapiro, J., Karapetis, C. S., Simes, J., Jonker, D., Tu, D., O'Callaghan, C., Chen, E., & Liu, G. (2025). Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.24.00114

Vancouver

Nicholls DL, Xu MC, Zhan L, Sharma D, Hueniken K, Chiasson K, et al. Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci.24.00114

BibTeX
@article{Nicholls2025,
  author = {Nicholls, Danielle Lilly and Xu, Maria C and Zhan, Luna and Sharma, Divya and Hueniken, Katrina and Chiasson, Kaitlyn and Wahba, Mary and Brown, M Catherine and Grant, Benjamin and Shapiro, Jeremy and Karapetis, Christos S and Simes, John and Jonker, Derek and Tu, Dongsheng and O'Callaghan, Christopher and Chen, Eric and Liu, Geoffrey},
  title = {Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials},
  journal = {JCO Clinical Cancer Informatics},
  year = {2025},
  doi = {10.1200/cci.24.00114}
}
Kostenlos starten →